Fairvalue-Calculator Fairvalue-Calculator
EN DE

Gongwin Biopharm Holdings (6617) Fair Value & Analysis

Healthcare · TW · Market cap 8.7B TWD

Price65.90 TWD
Fair Value62.69 TWD
Upside-4.9%
Quality95/100
Evidence: Low Range 47.02 TWD – 78.36 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Gongwin Biopharm Holdings (6617) currently trades at 65.90 TWD, while our model-based Fair Value estimate is 62.69 TWD — implying the stock looks roughly 4.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company also develops animal medicines; engaged in the pet medical business; and wholesale and retail of the medical equipment. Gongwin Biopharm Holdings Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Gongwin Biopharm Holdings (6617) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 62.69 TWD versus a price of 65.90 TWD — about −5% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6617?
Our 21-model fair value for Gongwin Biopharm Holdings is 62.69 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 65.90 TWD.
What is the quality score of 6617?
Gongwin Biopharm Holdings has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.